IL289290B1 - Benzyl-triazole compounds are substituted for CBL-B inhibition, and their additional uses - Google Patents

Benzyl-triazole compounds are substituted for CBL-B inhibition, and their additional uses

Info

Publication number
IL289290B1
IL289290B1 IL289290A IL28929021A IL289290B1 IL 289290 B1 IL289290 B1 IL 289290B1 IL 289290 A IL289290 A IL 289290A IL 28929021 A IL28929021 A IL 28929021A IL 289290 B1 IL289290 B1 IL 289290B1
Authority
IL
Israel
Prior art keywords
cbl
inhibition
substituted benzyl
further uses
triazole compounds
Prior art date
Application number
IL289290A
Other languages
English (en)
Hebrew (he)
Other versions
IL289290A (en
Inventor
Arthur T Sands
Neil F Bence
Christoph W Zapf
Frederick Cohen
Chenbo Wang
Thomas Cummins
Hiroko Tanaka
Hunter Shunatona
Mario Cardozo
Dahlia Weiss
Jennifa Gosling
Original Assignee
Nurix Therapeutics Inc
Arthur T Sands
Neil F Bence
Christoph W Zapf
Frederick Cohen
Chenbo Wang
Thomas Cummins
Hiroko Tanaka
Hunter Shunatona
Mario Cardozo
Dahlia Weiss
Jennifa Gosling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc, Arthur T Sands, Neil F Bence, Christoph W Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling filed Critical Nurix Therapeutics Inc
Publication of IL289290A publication Critical patent/IL289290A/en
Publication of IL289290B1 publication Critical patent/IL289290B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL289290A 2019-06-26 2020-06-26 Benzyl-triazole compounds are substituted for CBL-B inhibition, and their additional uses IL289290B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866914P 2019-06-26 2019-06-26
US201962880285P 2019-07-30 2019-07-30
US201962888870P 2019-08-19 2019-08-19
US201962888845P 2019-08-19 2019-08-19
PCT/US2020/039957 WO2020264398A1 (en) 2019-06-26 2020-06-26 Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof

Publications (2)

Publication Number Publication Date
IL289290A IL289290A (en) 2022-02-01
IL289290B1 true IL289290B1 (en) 2026-04-01

Family

ID=71662363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289290A IL289290B1 (en) 2019-06-26 2020-06-26 Benzyl-triazole compounds are substituted for CBL-B inhibition, and their additional uses

Country Status (11)

Country Link
US (3) US11401267B2 (https=)
EP (1) EP3990117A1 (https=)
JP (1) JP7831995B2 (https=)
KR (1) KR20220026581A (https=)
CN (1) CN114364670B (https=)
AU (2) AU2020303696B2 (https=)
BR (1) BR112021026241A2 (https=)
CA (2) CA3294689A1 (https=)
IL (1) IL289290B1 (https=)
MX (2) MX2021015675A (https=)
WO (1) WO2020264398A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EP3953346A1 (en) * 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
MX2021015675A (es) * 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
EP4034141A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
AR124800A1 (es) * 2021-02-03 2023-05-03 Genentech Inc Lactamas como inhibidores cbl-b
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
AU2022256074A1 (en) * 2021-04-09 2023-11-02 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
BR112023021068A2 (pt) * 2021-04-16 2024-01-23 Hotspot Therapeutics Inc Compostos, composições e métodos para tratar câncer
WO2022272248A1 (en) * 2021-06-21 2022-12-29 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
AU2022379494A1 (en) 2021-10-26 2024-05-30 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
WO2023072273A1 (zh) * 2021-10-29 2023-05-04 先声再明医药有限公司 作为cbl-b抑制剂的并环化合物
JP2024542117A (ja) * 2021-11-05 2024-11-13 ジェネンテック， インコーポレイテッド Ｃ－ｃｂｌに対して選択的なｃｂｌ－ｂ阻害剤としてのラクタム
WO2023081486A1 (en) * 2021-11-08 2023-05-11 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
TW202342013A (zh) * 2022-02-10 2023-11-01 英屬開曼群島商百濟神州有限公司 雜環化合物、其組成物及用其進行治療之方法
CN116715632B (zh) * 2022-03-07 2025-09-30 苏州恩华生物医药科技有限公司 螺[环丁烷1,4′-异喹啉]酮类衍生物顺反异构体的制备方法
WO2023170608A1 (en) * 2022-03-09 2023-09-14 Orum Therapeutics, Inc. Activators of effector t cells
WO2023205180A1 (en) * 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
CN119212724A (zh) * 2022-05-09 2024-12-27 上海先博生物科技有限公司 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents
CN119998282A (zh) * 2022-07-12 2025-05-13 热点治疗公司 固体形式和使用方法
EP4554582A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation
EP4554930A1 (en) * 2022-07-12 2025-05-21 Hotspot Therapeutics, Inc. Methods of preparation of heterocyclic compounds
JP2025523057A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド がん処置における使用のためのｃｂｌ－ｂ阻害剤及び抗ｐｄ１／抗ｐｄ－ｌ１
AR129946A1 (es) * 2022-07-18 2024-10-16 Insilico Medicine Ip Ltd Inhibidores de cbl-b y métodos de uso de los mismos
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
JP2025525947A (ja) 2022-08-16 2025-08-07 グレンマーク ファーマシューティカルズ エルティーディー Ｃｂｌ－ｂ阻害剤としての置換ピリジノン化合物
WO2024062363A1 (en) * 2022-09-21 2024-03-28 Glenmark Pharmaceuticals Ltd Bicyclic heterocyclic compounds as cbl-b inhibitors
WO2024074977A1 (en) * 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024081311A1 (en) * 2022-10-11 2024-04-18 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
WO2024086730A1 (en) * 2022-10-19 2024-04-25 Hotspot Therapeutics, Inc. Heterocyclic cbl-b inhibitors for the treatment of cancer
WO2024105563A1 (en) * 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024131939A1 (en) * 2022-12-23 2024-06-27 Insilico Medicine Ip Limited Cbl-b inhibitors and methods of uses thereof
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
CN120584113A (zh) * 2023-01-19 2025-09-02 广州宇繁南图生物科技有限公司 一种杂环化合物及其制备方法和应用
WO2024153246A1 (zh) * 2023-01-20 2024-07-25 海南先声再明医药股份有限公司 取代的三环化合物及其应用
TW202435863A (zh) 2023-01-28 2024-09-16 芬蘭商奧利安公司 Cbl-b抑制劑
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
AR132644A1 (es) 2023-05-09 2025-07-16 Genentech Inc 3-fenil-isoindolin-1-onas 6-sustituidas, como inhibidores selectivos de cbl-b sobre c-cbl
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024255762A1 (zh) * 2023-06-13 2024-12-19 上海齐鲁制药研究中心有限公司 Cbl-b抑制剂
CN121816192A (zh) 2023-09-14 2026-04-07 因斯布鲁克医科大学 通过抑制NR2f6增强CAR-T细胞疗效
WO2025223343A1 (zh) * 2024-04-22 2025-10-30 杭州中美华东制药有限公司 作为Cbl-b抑制剂的化合物
WO2025243317A1 (en) * 2024-05-20 2025-11-27 Jubilant Biosys Limited Substituted bicyclic sulfonamide derivatives as modulators of cbl-b
WO2026022749A2 (en) 2024-07-26 2026-01-29 Aurigene Oncology Limited Cbl-b inhibitors
WO2026040995A1 (zh) * 2024-08-19 2026-02-26 北京望实智慧科技有限公司 用作Cbl-b抑制剂的化合物
CN120000656B (zh) * 2025-03-20 2025-11-07 北京大学 小分子化合物nx-1607在制备治疗肝纤维化的产品中的应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
CA2437248A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2004099388A2 (en) 2003-03-05 2004-11-18 Proteologics, Inc. Cbl-b polypeptides, complexes and related methods
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CN101365806B (zh) 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
ES2566502T3 (es) 2006-09-13 2016-04-13 The Trustees Of Columbia University In The City Of New York Agentes y métodos para provocar una respuesta inmune antitumoral
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
CA2710462C (en) 2008-02-05 2015-11-24 F. Hoffmann-La Roche Ag Pyridinones and pyridazinones
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
KR101862327B1 (ko) 2010-05-07 2018-05-29 질레드 코네티컷 인코포레이티드 피리돈 및 아자-피리돈 화합물 및 사용 방법
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
US20130110678A1 (en) 2011-11-02 2013-05-02 Apple Inc. Purchasing a product in a store using a mobile device
WO2013067264A1 (en) 2011-11-03 2013-05-10 Genentech, Inc. 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
KR20150054994A (ko) 2012-09-13 2015-05-20 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
BR112017025986A2 (pt) 2015-06-02 2018-08-14 Pharmacyclics Llc inibidores de tirosina quinase de bruton.
EP3325475B1 (en) 2015-07-17 2020-03-18 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as hdac inhibitors
EP3138905A1 (en) 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
EP3254701A1 (en) 2016-06-09 2017-12-13 IMBA-Institut für Molekulare Biotechnologie GmbH Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
US10842878B2 (en) 2016-11-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
WO2019148005A1 (en) * 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
WO2021021761A1 (en) 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
EP4034141A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for expansion of immune cells
US20230024442A1 (en) 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERRY LJ, ET AL., ADOPTIVE IMMUNOTHERAPY FOR CANCER: THE NEXT GENERATION OF GENE-ENGINEERED IMMUNE CELLS, 30 October 2009 (2009-10-30) *
HALL M, ET AL., EXPANSION OF TUMOR-INFILTRATING LYMPHOCYTES (TIL) FROM HUMAN PANCREATIC TUMORS, 31 December 2016 (2016-12-31) *

Also Published As

Publication number Publication date
MX2025000627A (es) 2025-03-07
JP2022538174A (ja) 2022-08-31
US12234230B2 (en) 2025-02-25
KR20220026581A (ko) 2022-03-04
US20250136590A1 (en) 2025-05-01
JP7831995B2 (ja) 2026-03-17
US20210053961A1 (en) 2021-02-25
AU2020303696A1 (en) 2022-01-06
IL289290A (en) 2022-02-01
CA3144450A1 (en) 2020-12-30
MX2021015675A (es) 2022-02-03
US11401267B2 (en) 2022-08-02
CA3294689A1 (en) 2026-03-02
AU2020303696B2 (en) 2026-04-09
EP3990117A1 (en) 2022-05-04
BR112021026241A2 (pt) 2022-06-07
US20230150991A1 (en) 2023-05-18
AU2026202030A1 (en) 2026-04-02
CN114364670B (zh) 2025-06-13
WO2020264398A1 (en) 2020-12-30
CN114364670A (zh) 2022-04-15

Similar Documents

Publication Publication Date Title
IL289290A (en) Substituted benzyltriazole compounds for cbl-b inhibition, and other uses thereof
IL288236A (en) 3,2-dihydroquinazoline compounds as inhibitors of nav1.8
SG11202104326TA (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
IL285302A (en) Compounds, preparations and methods
IL276082B1 (en) DNA-pk inhibitor compounds, preparations containing them and their uses
IL276080A (en) DNA-pk suppressor compounds, UTP-containing preparations and their uses
IL288816A (en) Aminobenzazepine compounds, immunoconjugates and uses thereof
GB201910389D0 (en) Novel compounds, methods for their manufacture, and uses thereof
IL292536B1 (en) Heterocyclic compounds inhibit RIP1
GB2603386B (en) Selective dihydropyrrolopyrimidine JAK2 inhibitors
IL284765A (en) 8,1-naphthyridinone compounds and their uses
LT3634975T (lt) 15.beta.-[3-propanamido]-pakeisti estra-1,3,5(10)-trien-17-onų 17-oksimai, skirti 17.beta.-hidroksisteroidų dehidrogenazių slopinimui
IL287120A (en) Compounds, preparations and methods
NO20190133A1 (en) Fremgangsmåte for inspeksjon av rør
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof
ES3063388T3 (en) Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds
EP4025564A4 (en) NITRIFICATION INHIBITORS
GB202005952D0 (en) Regalsystem, RegaLseitenwand und Seitenwandteil
HK40073757A (en) Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
GB202011508D0 (en) .
HK40069890A (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
GB201905370D0 (en) Elastate inhibition
HK40071165A (en) Inhibiting usp19
HK40070698A (en) Inhibiting usp36
HK40072132A (en) Macromolecule-supported thienoazepine compounds, and uses thereof